We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: cervical cancer
MedXY News
EnglishTag

cervical cancer

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical Trial
newschemotherapyKEYNOTE-826

Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical Trial

By MedXY|Sep 15, 2026

Five-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.

Minimally Invasive Radical Hysterectomy Without Uterine Manipulator vs Open Surgery for Early-Stage Cervical Cancer: Comparative Outcomes from a Large Propensity-Matched Cohort
news
Phẫu thuật xâm lấn tối thiểu
uterine manipulator

Minimally Invasive Radical Hysterectomy Without Uterine Manipulator vs Open Surgery for Early-Stage Cervical Cancer: Comparative Outcomes from a Large Propensity-Matched Cohort

By MedXY|Sep 12, 2026

This retrospective study compares oncologic and perioperative outcomes of minimally invasive radical hysterectomy without uterine manipulator versus open radical hysterectomy in early-stage cervical cancer, showing comparable survival but i

Trends in Incidence, Mortality, and Survival of Endometrial, Ovarian, and Cervical Cancers in Young Nordic Women: Insights from 40 Years of Registry Data
newsincidencesurvival

Trends in Incidence, Mortality, and Survival of Endometrial, Ovarian, and Cervical Cancers in Young Nordic Women: Insights from 40 Years of Registry Data

By MedXY|Aug 22, 2026

This article analyzes 40-year trends in incidence, mortality, and survival of endometrial, ovarian, and cervical cancers among Nordic women aged 0-49, highlighting evolving epidemiology and implications for age-specific prevention.

Quality of Life and Morbidity Outcomes After Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-Stage Cervical Cancer: Insights from the SENTIX Study
newsSentinel Lymph Node Biopsylymphoedema

Quality of Life and Morbidity Outcomes After Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-Stage Cervical Cancer: Insights from the SENTIX Study

By MedXY|Aug 18, 2026

The SENTIX study demonstrates that sentinel lymph node biopsy preserves quality of life, reduces lymphoedema incidence, and lowers early postoperative complications compared to pelvic lymphadenectomy in early-stage cervical cancer patients.

Revisiting HER2 Status in Recurrent Cervical Cancer: Clinical Implications of Dynamic Expression for Targeted Therapy
newsrecurrenceHER2

Revisiting HER2 Status in Recurrent Cervical Cancer: Clinical Implications of Dynamic Expression for Targeted Therapy

By MedXY|Aug 18, 2026

HER2 expression in recurrent cervical cancer varies notably by histology and recurrence site, underscoring the importance of reassessment to guide HER2-targeted treatments effectively.

Safety and Long-Term Benefits of Hormone Therapy After Chemoradiation in Young Cervical Cancer Survivors
newslong-term outcomesMenopause

Safety and Long-Term Benefits of Hormone Therapy After Chemoradiation in Young Cervical Cancer Survivors

By MedXY|Aug 18, 2026

Hormone therapy initiated within one year after chemoradiotherapy in young patients with locally advanced cervical cancer is associated with reduced metabolic, skeletal, and cerebrovascular risks, and improved survival without increased onc

Enhancing Triage of Non-16/18 High-Risk HPV Cervical Lesions Using FAM19A4, SOX1, and PAX1 Methylation Testing
newstriageHPV

Enhancing Triage of Non-16/18 High-Risk HPV Cervical Lesions Using FAM19A4, SOX1, and PAX1 Methylation Testing

By MedXY|Aug 18, 2026

FAM19A4, SOX1, and PAX1 methylation assays demonstrate high diagnostic accuracy for identifying CIN3+ among non-16/18 hrHPV-positive women, outperforming cytology and reducing unnecessary colposcopies.

Pelvic Exenteration for Recurrent Cervical Cancer Can Deliver Long-Term Survival, but Survivorship Burden Remains Substantial
OB/GYN & Women's Healthsurvivorshipquality of life

Pelvic Exenteration for Recurrent Cervical Cancer Can Deliver Long-Term Survival, but Survivorship Burden Remains Substantial

By MedXY|Aug 18, 2026

A mixed-methods study suggests pelvic exenteration offers meaningful long-term survival in selected patients with recurrent cervical cancer, while qualitative data reveal persistent physical, social, and sexual burdens that standardized qua

Cost-effectiveness of Pembrolizumab for FIGO 2014 Stage III-IVA Cervical Cancer in the United States
newsCost-Effectivenesspembrolizumab

Cost-effectiveness of Pembrolizumab for FIGO 2014 Stage III-IVA Cervical Cancer in the United States

By MedXY|Aug 18, 2026

Pembrolizumab plus chemoradiotherapy improved survival and quality-adjusted survival for FIGO 2014 stage III-IVA cervical cancer and was projected to be cost-effective in the U.S. at a $150,000/QALY threshold.

newscervical cancerHPV

New Cervical Cancer Screening Guidelines: Patient-Collected HPV Tests Now Recommended

By MedXY|Apr 30, 2026

Introduction and Context Despite being highly preventable, cervical cancer remains a significant health threat. The…

ACOG Endorses Updated 2026 Cervical Cancer Screening Guidelines: Key Changes and Implications
newscervical cancerHPV testing

ACOG Endorses Updated 2026 Cervical Cancer Screening Guidelines: Key Changes and Implications

By MedXY|Apr 26, 2026

The American College of Obstetricians and Gynecologists (ACOG) has qualifiedly endorsed the 2026 WPSI cervical cancer screening guidelines. This article details the core recommendations, highlights key updates including self-collection opti

Immunotherapy Shows Consistent Efficacy in Recurrent Gynecologic Cancers Regardless of Prior Radiation Field Location
newscervical cancerEndometrial Cancer

Immunotherapy Shows Consistent Efficacy in Recurrent Gynecologic Cancers Regardless of Prior Radiation Field Location

By MedXY|Apr 6, 2026

This retrospective study challenges the assumption that prior radiation limits immunotherapy effectiveness in recurrent endometrial and cervical cancers, finding no significant difference in response rates or survival outcomes based on recu

The Shift Toward De-escalation: Why Radical Trachelectomy Is Losing Ground in Early-Stage Cervical Cancer
newscervical cancerFertility-Sparing Surgery

The Shift Toward De-escalation: Why Radical Trachelectomy Is Losing Ground in Early-Stage Cervical Cancer

By MedXY|Mar 15, 2026

A multi-database analysis reveals a significant decline in trachelectomy utilization since 2016. With comparable 10-year survival rates between trachelectomy and conization, clinical practice is rapidly shifting toward less radical, fertili

Optimizing Cervical Cancer Screening for Women Living with HIV: New Data Supports Starting at Age 25
newscervical cancerHIV/AIDS

Optimizing Cervical Cancer Screening for Women Living with HIV: New Data Supports Starting at Age 25

By MedXY|Feb 19, 2026

A large-scale meta-analysis reveals age-specific risks for cervical precancer in women living with HIV, justifying the WHO recommendation to initiate screening at age 25 with 3–5 year intervals to mitigate high recurrence and progression ra

Simple vs Radical Hysterectomy: Balancing Survival Outcomes and Quality of Life in Early Cervical Cancer
newscervical cancerhysterectomy

Simple vs Radical Hysterectomy: Balancing Survival Outcomes and Quality of Life in Early Cervical Cancer

By MedXY|Dec 17, 2025

Evidence suggests simple hysterectomy with pelvic lymphadenectomy may offer similar survival outcomes to radical hysterectomy in early-stage cervical cancer, with fewer adverse events and better short-term quality of life.

Long-Term Effectiveness of HPV Screen-and-Treat Strategy Versus Cytology in Cervical Cancer Screening: Insights from El Salvador’s CAPE Program
newscervical cancerHPV Screening

Long-Term Effectiveness of HPV Screen-and-Treat Strategy Versus Cytology in Cervical Cancer Screening: Insights from El Salvador’s CAPE Program

By MedXY|Oct 31, 2025

A 5-year follow-up study in El Salvador demonstrates that primary HPV screen-and-treat significantly reduces CIN2+ detection and HPV positivity compared to cytology, supporting extended screening intervals in low-resource settings.

Review for Cervical Cancer Screening
newscervical cancerHPV

Review for Cervical Cancer Screening

By MedXY|Oct 31, 2025

A comprehensive 2025 systematic review informing the Canadian Task Force finds cytology remains effective into the 60s, HPV-based strategies detect more precursors but increase colposcopy and false positives, and self-sampling improves upta

Revolutionizing Early-Stage Cervical Cancer Management: Insights from the SENTIX Sentinel Lymph Node Trial
newscervical cancerclinical trial

Revolutionizing Early-Stage Cervical Cancer Management: Insights from the SENTIX Sentinel Lymph Node Trial

By MedXY|Oct 25, 2025

The SENTIX trial shows that sentinel lymph node biopsy without full pelvic lymphadenectomy is safe in early-stage cervical cancer, potentially reducing surgical morbidity without compromising oncologic outcomes.

Reevaluating Lymph Node Management in Early-Stage Cervical Cancer: Sentinel Biopsy Alone Shows Promise
newscervical cancerLymphadenectomy

Reevaluating Lymph Node Management in Early-Stage Cervical Cancer: Sentinel Biopsy Alone Shows Promise

By MedXY|Oct 25, 2025

A large randomized trial finds sentinel lymph-node biopsy alone is noninferior to lymphadenectomy in early cervical cancer, with fewer complications and comparable survival outcomes.

Impact of Treatment Recommendation and Receipt on Survival in Older Women with Early-Stage Cervical Cancer
newscervical cancersurvival outcomes

Impact of Treatment Recommendation and Receipt on Survival in Older Women with Early-Stage Cervical Cancer

By MedXY|Oct 9, 2025

This study reveals that among women aged 65 and older with early-stage cervical cancer, those who receive recommended treatment—surgery and/or radiotherapy—exhibit significantly higher survival rates, emphasizing the need to overcome treatm

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities